The Veri-Q self-testing MGD-2001 Blood Glucose Monitoring System is intended for use in The quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from fingertips, palm, or forearm. The Veri-Q self-testing MGD-2001 Blood Glucose Monitoring System is intended to be used by a single patient and should not be shared. The Veri-Q self-testing MGD-2001 Blood Glucose Monitoring System is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The Veri-Q sclf-testing MGD-2001 Blood Glucose Monitoring System should not be used for the diagnosis of or screening for diabetes or for neonatal use. Alternative site testing should be done only during steady-state times (when glucose is not changing rapidly).

The Veri-Q self-testing MGS-01 test strips are for use with the Veri-Q self-testing MGD-2001 meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples drawn from fingertips, palm, or forearm.

The Veri-O self-testing Glucose Control Solutions are for use with the Veri-Q self-testing MGD-2001 meter and the Veri-Q self-testing MGS-01 test strips to check that the meter and test strips are working together properly and providing accurate results.

The Veri-Q plus MGD-2001 Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose (sugar) in fresh capillary whole blood drawn from fingertips, palm, or forearm. The Veri-Q plus MGD-2001 Blood Glucose Monitoring System is intended for testing outside the body (in vitro diagnostic use). The Veri-Q plus MGD-2001 Blood Glucose Monitoring System is intended for multi-patient use in a professional healthcare setting, as an aid to monitor the effectiveness of diabetes control. This system is only used with single-use, auto-disabling lancing devices. The Veri-O plus MGD-2001 Blood Glucose Monitoring System should not be used for the diagnosis of or screening for diabetes or for neonatal use. Alternative site testing should be done only during steady-state times (when glucose is not changing rapidly).

The Veri-O plus MGS-01 test strips are for use with the Veri-Q plus MGD-2001 meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples drawn from fingertips, palm, or forearm.

The Veri-Q plus Glucose Control Solutions are for use with the Veri-Q plus MGD-20(01 meter and the Veri-Q plus MGS-01 test strips to check that the meter and test strips are working together properly and providing accurate results.

Device Description

The proposed Veri-Q self testing/ plus MGD-2001 Blood Glucose Monitoring System consists of a meter, test strips, control solutions (3 levels), a lancing device and sterile lancets. The blood glucose test system is an in vitro diagnostic device designed for measuring the concentration of glucose in whole blood sample by means of an electrical current produced in the test strip and sent to the meter for measurement. The Veri-Q testing/plus MGD-2001 meter is a no-code meter, so the responsibility of coding has been removed from the user. Each individual test strip contains technology that allows it to automatically calibrate and code the meter once it is inserted.

AI/ML Overview

Here's an analysis of the acceptance criteria and supporting study for the Veri-Q self-testing/plus MGD-2001 Blood Glucose Monitoring System, based on the provided 510(k) summary:

The 510(k) summary states that "The testing for the Veri-Q self-testing/plus MGD-2001 Blood Glucose Monitoring System was performed in accordance with ISO 15197:2003." This standard specifies requirements for blood-glucose monitoring systems for self-testing and includes acceptance criteria for analytical performance. However, the exact acceptance criteria and reported device performance values are not explicitly stated in the provided text. To fulfill the request comprehensively, one would typically need to refer directly to ISO 15197:2003 and the full study report submitted with the 510(k). Since that detailed information is not available in the provided text, I will describe the kind of acceptance criteria typically found in ISO 15197:2003 and note the absence of specific reported performance.

A. Acceptance Criteria and Reported Device Performance

Acceptance Criteria (Typical ISO 15197:2003)	Reported Device Performance (from provided text)
For glucose concentrations < 4.2 mmol/L (75 mg/dL):	Not explicitly detailed.
- At least 95% of results shall fall within ±0.83 mmol/L (±15 mg/dL) of the reference method.	The document states, "The device passed all of the tests based on pre-determined Pass/Fail criteria."
For glucose concentrations ≥ 4.2 mmol/L (75 mg/dL):	Not explicitly detailed.
- At least 95% of results shall fall within ±20% of the reference method.	This implies the device met the ISO 15197:2003 criteria.
Combined Criteria (Overall Accuracy):	Not explicitly detailed.
- At least 95% of all measured glucose values shall fall within the respective ranges specified above.
- Also typically includes requirements for precision (repeatability and intermediate precision), linearity, effects of interfering substances, and user performance.

B. Sample Size and Data Provenance for the Test Set

Sample Size: The provided 510(k) summary does not specify the exact sample size used for the performance testing. It only states that "Clinical evaluation included method comparison, user performance and alternative-site blood glucose measurement."
Data Provenance: The document does not explicitly state the country of origin of the data or whether the study was retrospective or prospective.

C. Number of Experts and Qualifications for Ground Truth

The document does not provide information on the number of experts used or their qualifications for establishing ground truth. For blood glucose monitoring systems, ground truth is typically established using a highly accurate laboratory reference method (e.g., YSI analyzer) operated by trained laboratory professionals, rather than "experts" in the traditional sense of medical specialists reviewing images or clinical cases.

D. Adjudication Method for the Test Set

Adjudication methods (e.g., 2+1, 3+1) are typically used when multiple human readers or experts are involved in reviewing specific outputs or making diagnoses. This is not applicable to the type of performance study (analytical accuracy against a reference method) described for a blood glucose monitoring system. Therefore, no adjudication method would be listed.

E. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

Was it done? No, an MRMC comparative effectiveness study was not performed. This type of study is relevant for imaging devices or algorithms that directly assist human interpretation in diagnostic tasks where human variability is a key factor. A blood glucose monitoring system directly measures a physiological parameter.
Effect Size: Not applicable.

F. Standalone Performance Study

Was it done? Yes, a standalone performance study was done. The "Performance Data" section states, "Clinical evaluation included method comparison, user performance and alternative-site blood glucose measurement. Non-clinical performance evaluations were conducted to establish the performance, functionality and reliability characteristics of the Veri-Q self-testing/plus MGD-2001 Blood Glucose Monitoring System." This describes evaluating the device's accuracy and performance independently.

G. Type of Ground Truth Used

The type of ground truth implied by performing testing "in accordance with ISO 15197:2003" and conducting "method comparison" is a highly accurate laboratory reference method for glucose measurement (e.g., a YSI Glucose Analyzer). The study compares the device's measurements to these reference values.

H. Sample Size for the Training Set

The document does not provide information on the sample size for a "training set." Blood glucose monitoring systems typically do not rely on machine learning models that require a distinct "training set" in the same way AI algorithms for image analysis do. Their development relies on engineering, chemical processes, and calibration against reference standards, rather than supervised learning from large datasets.

I. How Ground Truth for the Training Set Was Established

Not applicable, as a "training set" for a machine learning model is not relevant for this type of device. The accuracy of the device's fundamental measurement mechanism and calibration would be established against highly accurate laboratory reference methods as described in G.

Summary

{0}------------------------------------------------

510(k) Summary

K123016

This summary of 510(k)-safety and effectiveness information is being submitted in accordance with requirements of 21 CFR Part 807.92.

Date: -_ 06/01/2013

JUN 1 8 2013

1. Submitter:

MiCoBioMed Co., Ltd. 55-13, Singeonji-Dong, Anseong-Si, Gyenggi-Do, 456-781, Republic of Korea Tel : +82-31-8056-5940 Fax : +82-31-8056-5518

2. Submission Correspondent:

Priscilla Chung LK Consulting Group USA, Inc. 1515 E Katella Ave Unit 2115, Anaheim, CA 92805 Phone: 714-202-8637 Fax: 714-409-3357 Email: info@lkconsultinggroup.com

3. Device:

Proprietary Name:	Veri-Q self-testing MGD-2001 Blood Glucose. Monitoring System Veri-Q plus MGD-2001 Blood Glucose Monitoring System
Common Name:	Blood Glucose Test System
Classification Name:	System, Test, Blood Glucose, Over The Counter Glucose Oxidase Single(specified) analyte controls
Classification:	Class II, 21 CFR 862.1345
Classification Product Code:	NBW
Subsequent Product Codes	CGA, JJX

4. Predicate Device:

CareSens N(K083468) by i-SENS, Inc.

{1}------------------------------------------------

5. Description:

6. Indications for use:

6.1 Veri-Q self-testing MGD-2001 Blood Glucose Monitoring System

6.2 Veri-Q plus MGD-2001 Blood Glucose Monitoring System

{2}------------------------------------------------

7. Technological Characteristics:

The Veri-Q self-testing/plus MGD-2001 Blood Glucose Monitoring System has the same fundamental scientific technology as the predicate device. The indications for use, technology, design of glucose meter, and strips are almost the same. The major difference is that for the Veri-Q self-testing/plus meter, no coding is required on user side but the predicate device employs auto-coding method. There are also minor difference such as shelf life and memory capacity.

8. Performance Data:

The testing for the Veri-Q self-testing/plus MGD-2001 Blood Glucose Monitoring System was performed in accordance with ISO 15197:2003. Clinical evaluation included method comparison, user performance and alternative-site blood glucose measurement. Non-clinical performance evaluations were conducted to establish the performance, functionality and reliability characteristics of the Veri-Q self-testing/plus MGD-2001 Blood Glucose Monitoring System. The device passed all of the tests based on pre-determined Pass/Fail criteria.

9. Conclusions:

MiCoBioMed Co., Ltd. concludes that the Veri-O sclf-testing/plus MGD-2001 Blood Glucose Monitoring System is safe and effective also, substantially equivalent to the predicate device.

{3}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three wavy lines representing the department's mission. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the eagle.

Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

June 18, 2013

MiCoBioMed Co., Ltd. C/O Priscilla Chung C/O LK Consulting Group 1515 E. Katella Ave, Unit 2115 ANAHEIM CA 92805

Re: K123016

Trade/Device Name: Veri-Q self-testing MGD-2001 Blood Glucose Monitoring System Veri-Q plus MGD-2001 Blood Glucose Monitoring System

Regulation Number: 21 CFR 862.1345 Regulation Name: Glucose test system Regulatory Class: II Product Code: NBW, CGA, JJX Dated: May 08, 2013 Received: May 09 2013

Dear Ms. Chung:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices-good-manufacturing-practice-labeling-and-prohibitions-against-misbranding-andadulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{4}------------------------------------------------

Page 2-Ms. Chung

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely yours.

Carol C. Benson -S for

Courtney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

Indications for Use

510(k) Number: K123016

Device Name: Veri-Q self-testing MGD-2001 Blood Glucose Monitoring System

Indication for use:

The Veri-Q self-testing MGD-2001 Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from fingertips, palm, or forearm. The Veri-Q self-testing MGD-2001 Blood Glucose Monitoring System is intended to be used by a single patient and should not be shared. The Veri-Q self-testing MGD-2001 Blood Glucose Monitoring System is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The Veri-Q self-testing MGD-2001 Blood Glucose Monitoring System should not be used for the diagnosis of on screening for diabetes or for neonatal use. Alternative site testing should be done only during steadystate times (when glucose is not changing rapidly),

The Veri-Q self-tcsting Glucose Control Solutions are for use with the Veri-Q self-testing MGD-2001 meter and the Veri-Q self-testing MGS-01 test strips to check that the meter and test strips are working together properly and providing accurate results.

Prescription Use AND/OR Over-The-Counter_Use_ (Part 21CFR801 Subpart D) (Part 21CFR807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE -- CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH. Office of In Vitro and Radiological Health (OIR)

Katherine Serrano -S

Division Sign-Off Office of In Vitro and Radiological Health Evaluation and Safety

510(k) K123016 Page I of 2

{6}------------------------------------------------

Indications for Use

510(k) Number: K123016

Device Name: Veri-Q plus MGD-2001 Blood Glucose Monitoring System

Indication for use:

The Veri-Q plus MGD-2001 Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose (sugar) in fresh capillary whole blood drawn from fingertips, palm, or forearm. The Veri-Q plus MGD-2001 Blood Glucose Monitoring System is intended for testing outside the body (in vitro diagnostic use). The Veri-Q plus MGD-2001 Blood Glucose Monitoring System is intended for multi-patient use in a professional healtheare setting, as an aid to monitor the effectiveness of diabetes control. This system is only used with single-use, auto-disabling lancing devices. The Veri-Q plus MGD-2001 Blood Glucose Monitoring System should not be used for the diagnosis of or screening for diabetes or for neonatal use. Alternative site testing should be done only during steady-state times (when glucose is not changing rapidly).

The Veri-Q plus MGS-01 test strips are for use with the Veri-Q plus MGD-2001 meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples drawn from fingertips, palm, or forearm. The Veri-Q plus Glucose Control Solutions are for use with the Veri-Q plus MGD-2001 meter and the Veri-Q plus MGS-01 test strips to check that the meter and test strips are working together properly and providing accurate results.

Prescription Use AND/OR Over-The-Counter Use
(Part-21CFR801-Subpart-D) (Part 21CFR807 Sübpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE OF NEEDED) Concurrence of CDRH, Office of In Vitro and Radiological Health (OIR)

Katherine Serrano -S

Division Sign-Off Office of In Vitro and Radiological Health Evaluation and Safety

510(k) K123016 Page 2 of 2

Regulation Number and Section

§ 862.1345 Glucose test system.

(a)
Identification. A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.(b)
Classification. Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.